The active ingredient in DALIRESP tablets is roflumilast. Roflumilast and its active metabolite (roflumilast N-oxide) are selective phosphodiesterase 4 (PDE4) inhibitors.
DALIRESP® is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Limitations of Use
DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm.
Published Studies Related to Daliresp (Roflumilast)
Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge
in healthy subjects: a randomized placebo-controlled trial. 
of roflumilast in a human model of segmental bronchial endotoxin challenge... CONCLUSIONS: Roflumilast attenuated the endotoxin-induced influx of neutrophils
Effect of 1-year treatment with roflumilast in severe chronic obstructive
pulmonary disease. 
exacerbation frequency over 1 year in patients with stable COPD... CONCLUSIONS: In severe, stable COPD, PDE4 inhibition with roflumilast produced a
Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness
after allergen challenge. 
asthmatic response to allergen challenge... CONCLUSIONS: Roflumilast attenuated allergen-induced AHR in patients with mild
Efficacy and safety of roflumilast in patients with stable chronic obstructive
pulmonary disease: a meta-analysis. 
AIM: To assess the efficacy and safety of roflumilast in COPD patients... CONCLUSIONS: Roflumilast significantly reduces the mean exacerbation rate in COPD
High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor
to determine the absolute bioavailability of ROF in humans... CONCLUSION: ROF is rapidly absorbed after PO administration and exhibits high
Reports of Suspected Daliresp (Roflumilast) Side Effects
Decreased Appetite (37),
Weight Decreased (33),
Anxiety (22), more >>
Page last updated: 2014-11-30